Skip to main content
. 2022 Mar 2;9:799488. doi: 10.3389/fcvm.2022.799488

Table 2.

Prognostic values and management at the time of shock or cardiac arrest.

Non-ECMO (n = 15) ECMO (n = 25) P
Cardiac arrest, n (%) 11 (73.3) 15 (60.0) 0.392
Sudden cardiac arrest*, n (%) 8 (53.3) 12 (48.0) 0.744
CPR duration (min), mean (SD) 34.8 (20.8) 44.3 (22.4) 0.281
Right heart strain
RV strain on ECG, n (%) 6 (85.7) (n = 7) 16 (80.0) (n = 20) 0.738
RV dilation on echo, n (%) 2 (100.0) (n = 2) 19 (95.0) (n = 20) 0.746
RV/LV diameter ratio on CT, mean (SD) 2.5 (0.8) (n = 5) 1.9 (0.8) (n = 21) 0.100
RV/LV diameter ≥ 1.0 on CT, n (%) 5 (100.0) (n = 5) 18 (85.7) (n = 21) 0.369
Laboratory finding
PH, mean (SD) 7.26 (0.13) (n = 10) 7.13 (0.24) (n = 22) 0.056
Bicarbonate (mmol/L), mean (SD) 17.3 (4.3) (n = 10) 16.8 (7.6) (n = 22) 0.845
SBE, median (IQR) −5.8 (−15.7 to −4.0) (n = 10) −12.5 (−19.6 to −4.1) (n = 22) 0.200
PaO2/FiO2 ratio (mmHg), median (IQR) 112.5 (57.9 to 262.9) (n = 8) 111.25 (18.45 to 185.13) (n = 22) 0.708
Troponin I (ng/mL), median (IQR) 0.27 (0.12 to 0.90) (n = 8) 0.08 (0.029 to 0.329) (n = 23) 0.061
Time from shock to CPR/ECMO (hours), median (IQR) 0.0 (0.0 to 2.7) (n = 11) 0.6 (0.0 to 1.8) 0.483
Management
Mechanical ventilation, n (%) 13 (86.7) 25 (100.0) 0.061
Inotropic use, n (%) 15 (100.0) 22 (88.0) 0.163
Anticoagulation therapy 15 (100.0) 25 (100.0) >0.999
    Before shock/arrest, n (%) 10 (66.7) 9 (36.0) 0.060
Thrombolytic therapy, n (%) 3 (20.0) 9 (36.0) 0.285
    Before CPR/ECMO, n (%) 2 (13.3) 1 (4.0) 0.278
    After CPR/ECMO, n (%) 1 (6.7) 8 (32.0) 0.063
Pulmonary embolectomy, n (%) 0 (0.0) 0 (0.0) >0.999

CPR, cardiopulmonary resuscitation; CT, computed tomography; ECG, electrocardiogram; ECMO, veno-arterial extracorporeal membrane oxygenation; IQR, interquartile range; RV, right ventricle; RV/LV, right-to-left ventricular; SBE, standard base excess; SD, standard deviation.